The suppressive tumor microenvironment: a challenge in cancer immunotherapy.
about
Reactive Oxygen Species Regulate T Cell Immune Response in the Tumor MicroenvironmentAntibody-based immunotherapy for ovarian cancer: where are we at?The application of the fibroblast activation protein α-targeted immunotherapy strategyPeripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapyEffects of Fermented Mushroom of Cordyceps sinensis, Rich in Selenium, on Uterine Cervix Cancer.New insights into the role of EMT in tumor immune escape.Past, present and future targets for immunotherapy in ovarian cancerTrp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model.Antitumor and Adjuvant Activity of λ-carrageenan by Stimulating Immune Response in Cancer ImmunotherapyStabilin-1 expression in tumor associated macrophages.Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvDelicate balance among three types of T cells in concurrent regulation of tumor immunity.Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model.Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinomaImmunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapiesMyeloid-derived suppressor cells and myeloid regulatory cells in cancer and autoimmune disordersDendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer.Mechanisms of action of tasquinimod on the tumour microenvironment.Recent progress concerning CpG DNA and its use as a vaccine adjuvant.Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects.The Role of the Immune System in Ovarian Cancer and Implications on Therapy.The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report.Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy.Structural analysis and immunostimulatory activity of glycopeptides from Paecilomyces sinensis.Comparative assessment of humoral immune responses of aluminum hydroxide and oil-emulsion adjuvants in Influenza (H9N2) and Newcastle inactive vaccines to chickens.Endostatin enhances antitumor effect of tumor antigen-pulsed dendritic cell therapy in mouse xenograft model of lung carcinoma.Macrophage-specific RNA interference targeting via "click", mannosylated polymeric micelles.Age-related Dysregulation of Inflammation and Innate Immunity: Lessons Learned from Rodent Models.Purification and activity characterization of polysaccharides in the medicinal lichen Umbilicaria tornata from Taibai Mountain, China.Nanomaterials for cancer immunotherapy.Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model.Increased prevalence of tumour infiltrating immune cells in oropharyngeal tumours in comparison to other subsites: relationship to peripheral immunity.Matrix stiffness and tumor-associated macrophages modulate epithelial to mesenchymal transition of human adenocarcinoma cells.Crosstalk between M2 macrophages and glioma stem cells.Reduction-responsive shell-crosslinked micelles prepared from Y-shaped amphiphilic block copolymers as a drug carrier
P2860
Q26740114-3958F6E2-BB86-4526-8B20-CCDB0B64654FQ27000514-DF6B07FE-90DC-490B-B211-ACD03E1ED6B8Q28073437-0F6DF7B2-6A78-421F-995B-DDFEA1BB8E45Q28394867-909B4B74-EC67-4E72-A613-B94688ABB0E9Q33757561-F6921313-DD2F-4022-9A25-2647DB7E6BB5Q33869781-91D7828A-7B41-4EBD-8EF9-8BEBA744A70AQ35034010-0E0F34C5-CE1F-4815-9A1D-60CF66E56998Q35739956-2CD28B05-076B-4C0A-9223-C8CA007351BFQ35766482-DB7E600D-65D5-4E99-85A9-6CFFFB85029BQ36303595-BFA0C16B-7BA4-4C43-AC40-B81D935E304FQ36744405-A45D7581-2210-4FB4-8D10-C18A8BF1C81AQ36755513-1070E20F-15C7-455B-8364-7B35ED2F9B29Q36756833-0064391B-B492-4185-892D-CC1AE2C1800BQ36849038-DFDCBC96-98DC-450D-AC7E-42290B89B1CCQ37047061-23A7BDF0-AD21-418B-9CA7-C30D0427F70DQ37697695-D0FE7ACE-FACB-4AA2-8E84-0CBC0FC3F35AQ37945301-128F18FB-F23A-4DCB-893E-208EDD1C56C1Q37945305-158ABFA6-59DD-47FB-8A2B-ECE7295290B2Q38155757-40ABE8B4-EA9C-4830-BC9B-DB734648434DQ38168903-F2697ED2-D8DD-4F28-8EB2-8B6B0580D438Q38336989-3DA454A2-E664-4F61-97F6-2334D5D7D795Q38715211-9C2283E6-9200-44B5-9B7F-080EE450DD9EQ39271605-B6119DAC-24BB-4BD4-8B61-341FDA8DCAC3Q39328588-07D8EA3E-6ECA-4BE8-9D61-1C48BAA45EAAQ39971244-7AE4F5C1-B836-4ABE-B576-1113E84842B0Q40836206-34E2A22E-5CEF-43E8-9CDC-631B8032F388Q41062063-9BAFAE88-A3E8-4A73-A724-5FFA8A052725Q41240553-CDB32C00-9C45-4493-8E13-AED087048DADQ42275311-EACA0420-EE15-43B7-9D20-D0D2AE87DE46Q47772751-AF2DA712-82FE-4345-B979-795CA188F05EQ48646732-932C26F7-6039-4F49-A8DC-6E83C556FA14Q50020665-A4DCCABD-554B-4380-9B45-80E4421637A0Q50484749-78CBEBCD-6CB9-425D-AD9C-B1A21E64C843Q52338220-A32D99F8-627D-48E6-969D-5DE1D1C0C24EQ53735490-02108F96-3442-45EA-8EFB-C2FD6FA05DAAQ57364484-B5EB61DA-E46D-4843-B7E0-5111501980F4
P2860
The suppressive tumor microenvironment: a challenge in cancer immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The suppressive tumor microenvironment: a challenge in cancer immunotherapy.
@en
The suppressive tumor microenvironment: a challenge in cancer immunotherapy.
@nl
type
label
The suppressive tumor microenvironment: a challenge in cancer immunotherapy.
@en
The suppressive tumor microenvironment: a challenge in cancer immunotherapy.
@nl
prefLabel
The suppressive tumor microenvironment: a challenge in cancer immunotherapy.
@en
The suppressive tumor microenvironment: a challenge in cancer immunotherapy.
@nl
P2860
P356
P1476
The suppressive tumor microenvironment: a challenge in cancer immunotherapy.
@en
P2093
Elizabeth A Vasievich
Leaf Huang
P2860
P304
P356
10.1021/MP1004228
P407
P577
2011-05-05T00:00:00Z